MOLECURE
Live / Registered — Registered (as of 10 Dec 2024)
What this means for you
Registered since 10 Dec 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97180459
- Registration number
- 7599933
- Mark type
- Word mark
- Filed
- 20 Dec 2021
- Published for opposition
- 23 May 2023
- Registered
- 10 Dec 2024
- Attorney of record
- David Orms
Goods and services
- Class 042 — Scientific and technological services: Medical and pharmacological research services; research and development services in the field of antibodies; research and development services in the field of immunology; research and development in the pharmaceutical and biotechnology fields; drug discovery services; development of pharmaceutical preparations and medicines; research on the subject of pharmaceuticals; conducting clinical trials for others for pharmaceutical products; biological research, clinical research in the field of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer, and medical research; medical laboratory services; scientific laboratory services; analysis of human tissues for medical research; laboratory services, namely, laboratory research services, medical laboratory services, scientific laboratory services relating to the production of monoclonal antibodies; medical research and scientific analysis in the field of immunology and antibodies; scientific research for medical purposes in the area of cancerous diseases; biomedical research services; biological research; research relating to biotechnology; clinical research and medical research in the field of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer; chemical research and analysis services including analytical services relating to medicines, pharmaceutical preparations and biochemistry; research laboratories, namely, laboratory research in the field of chemistry; scientific and biotechnology research in the field of gene therapy; DNA screening for scientific research purposes; biological research, namely, cell separation research services; research and development services in the field of immunohistology; scientific research in the field of genetics and genetic engineering; consultancy relating to research and development in the field of therapeutics; product custom design and development of medical technology; services for the development of methods of testing, namely, development and establishment of testing specifications and procedures in the field of biotechnology and pharmaceutical fields; conducting technical project studies, namely, technical research in the field of pharmaceutical studies; preparation of project analysis studies, namely, conducting scientific study in the fields of medicine and biotechnology; technical consultancy relating to product development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; advisory services relating to scientific research; providing information about the results of clinical trials for others for pharmaceutical products
Owner
- MOLECURE SPÓLKA AKCYJNA, WARSZAWA POLAND, PL
- MOLECURE SPÓLKA AKCYJNA, WARSZAWA POLAND, PL
- MOLECURE SPÓLKA AKCYJNA, WARSZAWA POLAND, PL
- OncoArendi Therapeutics S.A., Warszawa, PL
Prosecution history
- 10 Dec 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 10 Dec 2024 — REGISTERED-PRINCIPAL REGISTER
- 14 Nov 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 14 Nov 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 14 Nov 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Nov 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 13 Nov 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 10 Oct 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 10 Oct 2024 — NON-FINAL ACTION E-MAILED
- 10 Oct 2024 — SU - NON-FINAL ACTION - WRITTEN
- 12 Sept 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 12 Sept 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 Sept 2024 — ASSIGNED TO LIE
- 24 Apr 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 24 Jan 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED